6533b861fe1ef96bd12c43a2
RESEARCH PRODUCT
Metal Ions and Metal Complexes in Alzheimer's Disease.
Angelo SpinelloRiccardo BonsignoreGiampaolo BaroneBernhard K. KepplerAlessio Terenzisubject
0301 basic medicineStereochemistryMetal ions in aqueous solutionchemistry.chemical_elementProtein aggregationImagingPathogenesis03 medical and health scienceschemistry.chemical_compoundProtein AggregatesAlzheimer DiseaseCoordination ComplexesMetals HeavyDrug DiscoveryAD drugmedicineDementiaAnimalsHumansChelationMetal ionPharmacologyAmyloid beta-PeptidesDrug Discovery3003 Pharmaceutical ScienceAnti-aβ aggregating agentmedicine.diseaseCombinatorial chemistryRuthenium030104 developmental biologychemistrySettore CHIM/03 - Chimica Generale E InorganicaCurcuminMetal complexeAlzheimer's diseaseAlzheimer’s diseasedescription
Background: Alzheimer’s disease (AD) is the most common form of dementia that seriously affects daily life. Even if AD pathogenesis is still subject of debate, it is generally accepted that cerebral cortex plaques formed by aggregated amyloid-β (Aβ) peptides can be considered a characteristic pathological hallmark. It is well known that metal ions play an important role in the aggregation process of Aβ. Methods: This review focuses on the anti-Aβ aggregation activity of chelating ligands as well as on the use of metal complexes as diagnostic probes and as potential drugs. Conclusion: While chelating agents, such as curcumin or flavonoid derivatives, are currently used to capture metal ions responsible for Aβ aggregation, the potential application of platinum, ruthenium and cobalt complexes, among others, of several heterocyclic ligands, represents a promising new strategy to fight AD.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2015-04-19 | Current pharmaceutical design |